Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Health technology assessment methodology in metastatic renal cell carcinoma

Nature Reviews Urology volume 17, pages 3–5 (2020)Cite this article

Subjects

Cancer care is currently experiencing rapid development in novel therapeutics, with an associated rise in treatment costs. These changes not only create a critical challenge for therapeutic decision-making but also highlight the need to prioritize therapies of high clinical and economic value. Health technology assessment methodology is a novel approach that could help guide value-based decision-making.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Health technology assessment framework.

References

  1. Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 26, 1547–1573 (2015).

    Article  CAS  Google Scholar 

  2. Schnipper, L. E. et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J. Clin. Oncol. 33, 2563–2577 (2015).

    Article  Google Scholar 

  3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines) with NCCN evidence blocks. NCCN https://www.nccn.org/evidenceblocks (2018).

  4. Banta, D. What is technology assessment? Int. J. Technol. Assess. Health Care 25 (Suppl. 1), 7–9 (2009).

    Article  Google Scholar 

  5. Goodman, C. S. HTA 101: introduction to health technology assessment. NIH https://www.nlm.nih.gov/nichsr/hta101/HTA_101_FINAL_7-23-14.pdf (2014).

  6. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. NICE https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (2013).

  7. Lalani, A. A. et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions. Eur. Urol. 75, 100–110 (2019).

    Article  Google Scholar 

  8. Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).

    Article  CAS  Google Scholar 

  9. Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

    Ambica Parmar & Kelvin K. W. Chan

  2. Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada

    Kelvin K. W. Chan

Authors
  1. Ambica Parmar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelvin K. W. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ambica Parmar or Kelvin K. W. Chan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

CADTH: https://cadth.ca/

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Parmar, A., Chan, K.K.W. Health technology assessment methodology in metastatic renal cell carcinoma. Nat Rev Urol 17, 3–5 (2020). https://doi.org/10.1038/s41585-019-0257-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0257-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research